REPL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Replimune Class Action Lawsuit

Core Points - The Replimune Group, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934 by the company and its executives during the Class Period from November 22, 2024, to July 21, 2025 [1][3] - The lawsuit claims that Replimune made misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate, leading to a significant drop in stock price [3][4] Company Overview - Replimune is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its lead product candidate being RP1 (vusolimogene oderparepvec) [2] Legal Allegations - The class action lawsuit alleges that Replimune and its executives overstated the prospects of the IGNYTE trial, which resulted in the FDA's Complete Response Letter indicating that the trial was not well-controlled [3][4] - Following the FDA's announcement on July 22, 2025, Replimune's stock price fell by more than 77% [4] Class Action Process - Investors who purchased Replimune securities during the Class Period can seek to be appointed as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]